Boehringer Ingelheim announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. Striverdi Respimat is a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Striverdi Respimat is not indicated to treat asthma or acute deteriorations of COPD.
Approved by the U.S. Food and Drug Administration (FDA) in July 2014, Striverdi Respimat is a long-acting beta agonist (LABA) delivered via the Respimat inhaler, which provides a pre-measured amount of medicine in a slow-moving mist that helps patients inhale the medicine. The Respimat inhaler was developed to actively deliver medication in a way that does not depend on how fast air is breathed in from the inhaler.
“For over a half century, Boehringer Ingelheim has been a leader in discovering and developing new therapies for respiratory diseases. We’re proud to build upon our respiratory heritage by bringing Striverdi Respimat to market as a new COPD maintenance treatment option,” said Kathleen Dowd, senior vice president, Marketing, Boehringer Ingelheim Pharmaceuticals, Inc. “Approximately 15 million Americans have been told by a healthcare provider that they have COPD, and we believe Striverdi Respimat will be a welcome option for providers and patients alike.”
The FDA approval of Striverdi Respimat was based on data from eight Phase III clinical trials—including data from 48-week and 6-week duration trials—involving 4,450 people living with COPD. Patients involved in the 48-week studies were allowed to continue on their usual care with the exception of LABAs. Usual care included long- and short-acting anticholinergics, short-acting beta agonists, inhaled corticosteroids and xanthines.
Boehringer Ingelheim will offer a savings card that will allow most eligible patients to get Striverdi Respimat at no cost for a limited time, depending on their insurance provider. The savings card is available at www.Striverdi.com and can be activated at any pharmacy.
Date: October 8, 2014
Source: Boehringer Ingelheim
Filed Under: Drug Discovery